Electromed, Inc. delivered a standout performance in Q2 FY 2026 with record revenue of $18.9 million, marking the thirteenth consecutive quarter of revenue and profit growth, despite a strategic pullback in hospital shipments.

• Revenue increased by 16.3% year-over-year, driven by an 18.4% rise in the Home Care segment.
• Operating income grew 42.4% year-over-year to $3 million, with an operating income margin of 19%.
• The "Triple Down on Bronchiectasis" campaign launched to target a significant unmet need in bronchiectasis care, addressing potential expansion to 800,000 underserved patients.
• 25 new payer contracts were secured, expanding coverage to an additional 2.9 million lives, enhancing market access for SmartVest.
• Implementation of digital solutions, including the Smart Order e-prescribe, streamlined order fulfillment, with over one-third of orders now processed through this platform.